Nebenwirkungen · Farydak
Farydak 10 mg hard capsules Farydak 15 mg hard capsules Farydak 20 mg hard capsules · Abschnitt 4.8 · PDF-Seite 16
HOS-130490 · Präparat HOS-096923
Neutropenia Neutropenia was frequently reported on the basis of laboratory findings determined during the study (all grades: 75%). Most newly occurring severe neutropenia was grade 3 (28%), with considerably fewer cases of grade 4 (6.6%). While many patients developed neutropenia, febrile neutropenia only occurred in a fraction of treated patients (1.0%, both for CTC all grades and for grades 3 and 4). Patients with neutropenia are prone to infection, mostly upper respiratory tract infection or pneumonia. Only 0.3% of the patients were discontinued from the treatment due to neutropenia.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-01T17:42:00Z · SHA-256 58ca307f8694fb48a8bc74d8804d492564d6c11554c366f3220bc8e9fa2ab9be · Passage 57dbab51b2a5ec456b2a73ee25b2450e882690d51fb8c473ebed3470d94be3f9 · Zeichen 9934–10527 im Abschnitt